Cantex Pharmaceuticals Announces Sale of Equity Interest in Chimerix, Inc.
17267
post-template-default,single,single-post,postid-17267,single-format-standard,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1200,qode-theme-ver-18.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.1,vc_responsive

Cantex Pharmaceuticals Announces Sale of Equity Interest in Chimerix, Inc.

WESTON, FL – September 14, 2021 – Cantex Pharmaceuticals, Inc. (“Cantex”) today announced
that it has sold 6.5 million shares of Chimerix, Inc. in brokerage transactions at a price of $5.75
per share, less brokerage commissions and fees.

 

About Cantex Pharmaceuticals
Cantex Pharmaceuticals, Inc. is a privately-held, clinical stage pharmaceutical company focused
on the transformation of known drugs into innovative products with blockbuster potential.
Cantex is currently developing novel cancer treatments. Cantex’s pipeline consists of three
product candidates in Phase 2 and Phase 3 development for diseases with significant unmet
medical needs: Azeliragon for life-threatening and disabling complications of cancer,
Dicopp ®  for hematologic malignancies, and DSTAT, licensed to Chimerix, Inc., as a first-line
therapy of acute myeloid leukemia. For more information, please visit www.cantex.com.

 

Cantex Contacts

Investors:
Stephen G. Marcus, M.D.
(954) 315-3660
smarcus@cantex.com

or

Media:
Jason Rando
Tiberend Strategic Advisors
(917) 930-6346
jrando@tiberend.com